Role of everolimus in pancreatic neuroendocrine tumors

References

• Yao JC, Hassan M, Phan A et al. One hundred years after ‘carcinoid’: epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J. Clin. Oncol.26(18), 3063–3072 (2008).
   PubMed Web of Science ®Google Scholar
• Hauso O, Gustafsson BI, Kidd M et al. Neuroendocrine tumor epidemiology: contrasting Norway and North America. Cancer113(10), 2655–2664 (2008).
   PubMed Web of Science ®Google Scholar
• Metz DC, Jensen RT. Gastrointestinal neuroendocrine tumors: pancreatic endocrine tumors. Gastroenterology135(5), 1469–1492 (2008).
   PubMed Web of Science ®Google Scholar
• Klöppel G. Tumour biology and histopathology of neuroendocrine tumours. Best Pract. Res. Clin. Endocrinol. Metab.21(1), 15–31 (2007).
   PubMed Web of Science ®Google Scholar
• Panzuto F, Boninsegna L, Fazio N et al. Metastatic and locally advanced pancreatic endocrine carcinomas: analysis of factors associated with disease progression. J. Clin. Oncol.29(17), 2372–2377 (2011).
   PubMed Web of Science ®Google Scholar
• Rindi G, Klöppel G, Alhman H et al. TNM staging of foregut (neuro)endocrine tumors: a consensus proposal including a grading system. Virchows Arch.449(4), 395–401 (2006).
   PubMed Web of Science ®Google Scholar
• Chandrasekharappa SC, Guru SC, Manickam P et al. Positional cloning of the gene for multiple endocrine neoplasia-type 1. Science276(5311), 404–407 (1997).
   PubMed Web of Science ®Google Scholar
• Duerr EM, Chung DC. Molecular genetics of neuroendocrine tumors. Best Pract. Res. Clin. Endocrinol. Metab.21(1), 1–14 (2007).
   PubMedGoogle Scholar
• Jiao Y, Shi C, Edil BH et al. DAXX/ATRX, MEN1, and mTOR pathway genes are frequently altered in pancreatic neuroendocrine tumors. Science331(6021), 1199–1203 (2011).
   PubMed Web of Science ®Google Scholar
• Agarwal SK, Guru SC, Heppner C et al. Menin interacts with the AP1 transcription factor JunD and represses JunD-activated transcription. Cell96(1), 143–152 (1999).
   PubMed Web of Science ®Google Scholar
• Chung DC, Smith AP, Louis DN, Graeme-Cook F, Warshaw AL, Arnold A. A novel pancreatic endocrine tumor suppressor gene locus on chromosome 3p with clinical prognostic implications. J. Clin. Invest.100(2), 404–410 (1997).
   PubMedGoogle Scholar
• Ballian N, Loeffler AG, Rajamanickam V, Norstedt PA, Weber SM, Cho CS. A simplified prognostic system for resected pancreatic neuroendocrine neoplasms. HPB (Oxford)11(5), 422–428 (2009).
   Google Scholar
• Chen H, Hardacre JM, Uzar A, Cameron JL, Choti MA. Isolated liver metastases from neuroendocrine tumors: does resection prolong survival? J. Am. Coll. Surg.187(1), 88–92 (1998).
   PubMedGoogle Scholar
• Que FG, Nagorney DM, Batts KP, Linz LJ, Kvols LK. Hepatic resection for metastatic neuroendocrine carcinomas. Am. J. Surg.169(1), 36–42 (1995).
   PubMed Web of Science ®Google Scholar
• Touzios JG, Kiely JM, Pitt SC et al. Neuroendocrine hepatic metastases: does aggressive management improve survival? Ann. Surg.241(5), 776–783 (2005).
   PubMed Web of Science ®Google Scholar
• Gomez D, Malik HZ, Al-Mukthar A et al. Hepatic resection for metastatic gastrointestinal and pancreatic neuroendocrine tumours: outcome and prognostic predictors. HPB (Oxford)9(5), 345–351 (2007).
   Google Scholar
• Gupta S, Johnson MM, Murthy R et al. Hepatic arterial embolization and chemoembolization for the treatment of patients with metastatic neuroendocrine tumors: variables affecting response rates and survival. Cancer104(8), 1590–1602 (2005).
   PubMed Web of Science ®Google Scholar
• Eriksson BK, Larsson EG, Skogseid BM, Löfberg AM, Lörelius LE, Oberg KE. Liver embolizations of patients with malignant neuroendocrine gastrointestinal tumors. Cancer83(11), 2293–2301 (1998).
   PubMed Web of Science ®Google Scholar
• Kennedy AS, Dezarn WA, McNeillie P et al. Radioembolization for unresectable neuroendocrine hepatic metastases using resin 90Y-microspheres: early results in 148 patients. Am. J. Clin. Oncol.31(3), 271–279 (2008).
   PubMed Web of Science ®Google Scholar
• Rhee TK, Lewandowski RJ, Liu DM et al.90Y radioembolization for metastatic neuroendocrine liver tumors: preliminary results from a multi-institutional experience. Ann. Surg.247(6), 1029–1035 (2008).
   PubMed Web of Science ®Google Scholar
• Modlin IM, Pavel M, Kidd M, Gustafsson BI. Review article: somatostatin analogues in the treatment of gastroenteropancreatic neuroendocrine (carcinoid) tumours. Aliment. Pharmacol. Ther.31(2), 169–188 (2010).
   PubMed Web of Science ®Google Scholar
• Rinke A, Müller HH, Schade-Brittinger C et al. Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group. J. Clin. Oncol.27(28), 4656–4663 (2009).
   PubMed Web of Science ®Google Scholar
• Moertel CG, Lefkopoulo M, Lipsitz S, Hahn RG, Klaassen D. Streptozocin-doxorubicin, streptozocin-fluorouracil or chlorozotocin in the treatment of advanced islet-cell carcinoma. N. Engl. J. Med.326(8), 519–523 (1992).
   PubMed Web of Science ®Google Scholar
• Kouvaraki MA, Ajani JA, Hoff P et al. Fluorouracil, doxorubicin, and streptozocin in the treatment of patients with locally advanced and metastatic pancreatic endocrine carcinomas. J. Clin. Oncol.22(23), 4762–4771 (2004).
   PubMed Web of Science ®Google Scholar
• Cheng PN, Saltz LB. Failure to confirm major objective antitumor activity for streptozocin and doxorubicin in the treatment of patients with advanced islet cell carcinoma. Cancer86(6), 944–948 (1999).
   PubMed Web of Science ®Google Scholar
• Turner NC, Strauss SJ, Sarker D et al. Chemotherapy with 5-fluorouracil, cisplatin and streptozocin for neuroendocrine tumours. Br. J. Cancer102(7), 1106–1112 (2010).
   PubMed Web of Science ®Google Scholar
• Ekeblad S, Sundin A, Janson ET et al. Temozolomide as monotherapy is effective in treatment of advanced malignant neuroendocrine tumors. Clin. Cancer Res.13(10), 2986–2991 (2007).
   PubMed Web of Science ®Google Scholar
• Strosberg JR, Fine RL, Choi J et al. First-line chemotherapy with capecitabine and temozolomide in patients with metastatic pancreatic endocrine carcinomas. Cancer117(2), 268–275 (2011).
   PubMed Web of Science ®Google Scholar
• Kulke MH, Hornick JL, Frauenhoffer C et al. O6-methylguanine DNA methyltransferase deficiency and response to temozolomide-based therapy in patients with neuroendocrine tumors. Clin. Cancer Res.15(1), 338–345 (2009).
   PubMed Web of Science ®Google Scholar
• Cwikla JB, Sankowski A, Seklecka N et al. Efficacy of radionuclide treatment DOTATATE Y-90 in patients with progressive metastatic gastroenteropancreatic neuroendocrine carcinomas (GEP-NETs), a Phase II study. Ann. Oncol.21(4), 787–794 (2010).
   PubMed Web of Science ®Google Scholar
• Imhof A, Brunner P, Marincek N et al. Response, survival, and long-term toxicity after therapy with the radiolabeled somatostatin analogue [90Y-DOTA]-TOC in metastasized neuroendocrine cancers. J. Clin. Oncol.29(17), 2416–2423 (2011).
   PubMed Web of Science ®Google Scholar
• Teunissen JJ, Kwekkeboom DJ, Krenning EP. Quality of life in patients with gastroenteropancreatic tumors treated with [177Lu-DOTA0,Tyr3] octreotate. J. Clin. Oncol.22(13), 2724–2729 (2004).
   PubMed Web of Science ®Google Scholar
• Missiaglia E, Dalai I, Barbi S et al. Pancreatic endocrine tumors: expression profiling evidences a role for AKT–mTOR pathway. J. Clin. Oncol.28(2), 245–255 (2010).
   PubMed Web of Science ®Google Scholar
• Bergmann F, Breinig M, Höpfner M et al. Expression pattern and functional relevance of epidermal growth factor receptor and cyclooxygenase-2: novel chemotherapeutic targets in pancreatic endocrine tumors? Am. J. Gastroenterol.104(1), 171–181 (2009).
   PubMed Web of Science ®Google Scholar
• Terris B, Scoazec JY, Rubbia L et al. Expression of vascular endothelial growth factor in digestive neuroendocrine tumours. Histopathology32(2), 133–138 (1998).
   PubMed Web of Science ®Google Scholar
• Yao JC, Shah MH, Ito T, Bohas CL et al. Everolimus for advanced pancreatic neuroendocrine tumors. N. Engl. J. Med.364(6), 514–523 (2011).
   PubMed Web of Science ®Google Scholar
• Raymond E, Dahan L, Raoul JL et al. Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. N. Engl. J. Med.364(6), 501–513 (2011).
   PubMed Web of Science ®Google Scholar
• Sehgal SN, Baker H, Vézina C. Rapamycin (AY-22,989), a new antifungal antibiotic. Fermentation, isolation and characterization. J. Antibiot. (Tokyo)28(10), 727–732 (1975).
   PubMed Web of Science ®Google Scholar
• Budde K, Becker T, Arns W et al. Everolimus-based, calcineurin-inhibitor-free regimen in recipients of de-novo kidney transplants: an open-label, randomised, controlled trial. Lancet377(9768), 837–847 (2011).
   PubMed Web of Science ®Google Scholar
• Douros J, Suffness M. New antitumor substances of natural origin. Cancer Treat. Rev.8(1), 63–87 (1981).
   PubMed Web of Science ®Google Scholar
• Watanabe R, Wei L, Huang J. mTOR signaling, function, novel inhibitors, and therapeutic targets. J. Nucl. Med.52(4), 497–500 (2011).
   PubMed Web of Science ®Google Scholar
• von Wichert G, Jehle PM, Hoeflich A et al. Insulin-like growth factor-I is an autocrine regulator of chromogranin A secretion and growth in human neuroendocrine tumor cells. Cancer Res.60(16), 4573–4581 (2000).
   PubMed Web of Science ®Google Scholar
• Johannessen CM, Reczek EE, James MF, Brems H, Legius E, Cichowski K. The NF1 tumor suppressor critically regulates TSC2 and mTOR. Proc. Natl Acad. Sci. USA102(24), 8573–8578 (2005).
   PubMed Web of Science ®Google Scholar
• van Basten JP, van Hoek B, de Bruïne A, Arends JW, Stockbrügger RW. Ampullary carcinoid and neurofibromatosis: case report and review of the literature. Neth. J. Med.44(6), 202–206 (1994).
   PubMed Web of Science ®Google Scholar
• Lane HA, Wood JM, McSheehy PM et al. mTOR inhibitor RAD001 (everolimus) has antiangiogenic/vascular properties distinct from a VEGFR tyrosine kinase inhibitor. Clin. Cancer Res.15(5), 1612–1622 (2009).
   PubMed Web of Science ®Google Scholar
• Boulay A, Zumstein-Mecker S, Stephan C et al. Antitumor efficacy of intermittent treatment schedules with the rapamycin derivative RAD001 correlates with prolonged inactivation of ribosomal protein S6 kinase 1 in peripheral blood mononuclear cells. Cancer Res.64(1), 252–261 (2004).
   PubMed Web of Science ®Google Scholar
• Tanaka C, O’Reilly T, Kovarik JM et al. Identifying optimal biologic doses of everolimus (RAD001) in patients with cancer based on the modeling of preclinical and clinical pharmacokinetic and pharmacodynamic data. J. Clin. Oncol.26(10), 1596–1602 (2008).
   PubMedGoogle Scholar
• Tabernero J, Rojo F, Calvo E et al. Dose- and schedule-dependent inhibition of the mammalian target of rapamycin pathway with everolimus: a Phase I tumor pharmacodynamic study in patients with advanced solid tumors. J. Clin. Oncol.26(10), 1603–1610 (2008).
   PubMed Web of Science ®Google Scholar
• Wan X, Harkavy B, Shen N, Grohar P, Helman LJ. Rapamycin induces feedback activation of Akt signaling through an IGF-1R-dependent mechanism. Oncogene26(13), 1932–1940 (2007).
   PubMed Web of Science ®Google Scholar
• O’Reilly KE, Rojo F, She QB et al. mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt. Cancer Res.66(3), 1500–1508 (2006).
   PubMed Web of Science ®Google Scholar
• O’Donnell A, Faivre S, Burris HA 3rd et al. Phase I pharmacokinetic and pharmacodynamic study of the oral mammalian target of rapamycin inhibitor everolimus in patients with advanced solid tumors. J. Clin. Oncol.26(10), 1588–1595 (2008).
   PubMed Web of Science ®Google Scholar
• Kovarik JM, Sabia HD, Figueiredo J et al. Influence of hepatic impairment on everolimus pharmacokinetics: implications for dose adjustment. Clin. Pharmacol. Ther.70(5), 425–430 (2001).
   PubMed Web of Science ®Google Scholar
• Kovarik JM, Beyer D, Bizot MN, Jiang Q, Allison MJ, Schmouder RL. Pharmacokinetic interaction between verapamil and everolimus in healthy subjects. Br. J. Clin. Pharmacol.60(4), 434–437 (2005).
   PubMed Web of Science ®Google Scholar
• Yao JC, Phan AT, Chang DZ et al. Efficacy of RAD001 (everolimus) and octreotide LAR in advanced low- to intermediate-grade neuroendocrine tumors: results of a Phase II study. J. Clin. Oncol.26(26), 4311–4318 (2008).
   PubMed Web of Science ®Google Scholar
• Yao JC, Lombard-Bohas C, Baudin E et al. Daily oral everolimus activity in patients with metastatic pancreatic neuroendocrine tumors after failure of cytotoxic chemotherapy: a Phase II trial. J. Clin. Oncol.28(1), 69–76 (2010).
   PubMed Web of Science ®Google Scholar
• Pommier RF, Wolin EM, Panneerselvam A, Saletan S, Winkler RE, Van Cutsem E. Impact of prior chemotherapy on progression-free survival in patients (pts) with advanced pancreatic neuroendocrine tumors (pNET). Results from the RADIANT-3 trial. Presented at: 2010 ASCO Annual Meeting. Chicago, IL, USA, 4–8 June 2011.
   Google Scholar
• Shah MH, Lombard-Bohas C, Ito T. Everolimus in patients with advanced pancreatic neuroendocrine tumors (pNET), impact of somatostatin analog use on progression-free survival in the RADIANT-3 trial. Presented at: 2010 ASCO Annual Meeting. Chicago, IL, USA, 4–8 June 2011.
   Google Scholar
• Porta C, Osanto S, Ravaud A et al. Management of adverse events associated with the use of everolimus in patients with advanced renal cell carcinoma. Eur. J. Cancer47(9), 1287–1298 (2011).
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Escudier B, Oudard S et al. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled Phase III trial. Lancet372(9637), 449–456 (2008).
   PubMed Web of Science ®Google Scholar
• Strosberg JR, Lincy J, Winkler RE, Wolin EM, Lee H. Everolimus in patients with advanced pancreatic neuroendocrine tumors (pNET), updated results of a randomized, double-blind, placebo-controlled, multicenter, Phase III trial (RADIANT-3). Presented at: 2010 ASCO Annual Meeting. Chicago, IL, USA, 4–8 June 2011.
   Google Scholar
• Oudard S, Medioni J, Aylllon J et al. Everolimus (RAD001), an mTOR inhibitor for the treatment of metastatic renal cell carcinoma. Expert Rev. Anticancer Ther.9(6), 705–717 (2009).
   PubMed Web of Science ®Google Scholar